Arcturus Therapeutics’ treatment of cystic fibrosis was granted orphan status by the FDA, a post to the agency’s website shows.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARCT:
- Biotech Alert: Searches spiking for these stocks today
- Arcturus Therapeutics price target raised to $40 from $35 at Citi
- Arcturus Therapeutics reports Q3 EPS (61c), consensus ($1.69)
- Arcturus Therapeutics (ARCT) Q3 Earnings Cheat Sheet
- Acelyrin appoints Patricia Turney as chief technical operations officer
